BACKGROUND AND PURPOSE: The standard treatment for non-metastatic stage III/IV squamous cell carcinoma of the head and neck varies worldwide. This study compared the outcomes of radiochemotherapy alone to surgery followed by radio(chemo)therapy (radiotherapy plus/minus concurrent chemotherapy). PATIENTS AND METHODS: Data from 148 patients treated with radiochemotherapy alone were matched to 148 patients treated with surgery plus radio(chemo)therapy. Groups were matched 1:1 for nine potential prognostic factors including age, gender, performance status, tumor site, histologic grade, T category, N category, AJCC stage, and hemoglobin level before radiotherapy, and compared for locoregional control, metastases-free survival, and overall survival. RESULTS: Locoregional control rates at 1, 2, and 3 years were 81%, 73%, and 67% after surgery plus radio(chemo)therapy and 81%, 74%, and 65% after radiochemotherapy alone (p = 0.89). Metastases-free survival rates were 86%, 80%, and 75% after surgery plus radio(chemotherapy) versus 87%, 80%, and 72% after radiochemotherapy alone (p = 0.57). Overall survival rates were 80%, 64%, and 63% after surgery plus radio(chemo)therapy versus 83%, 68%, and 60% after radiochemotherapy alone (p = 0.96). On multivariate analyses, T category (p < 0.001), N category (p = 0.004), and hemoglobin level prior to radiotherapy (p < 0.001) were associated with locoregional control. Histologic grade (p = 0.045), T category (p < 0.001), N category (p = 0.003), and hemoglobin level prior to radiotherapy (p < 0.001) were associated with metastases-free survival. Histologic grade (p = 0.030), ECOG performance status (p = 0.033), T category (p = 0.007), N category (p = 0.024) and hemoglobin level before radiotherapy (p < 0.001) were associated with overall survival. CONCLUSION: Outcomes of radiochemotherapy alone appeared similar to those of surgery plus radio(chemo)therapy. Randomized trials comparing both treatments for different tumor sites are warranted.
BACKGROUND AND PURPOSE: The standard treatment for non-metastatic stage III/IV squamous cell carcinoma of the head and neck varies worldwide. This study compared the outcomes of radiochemotherapy alone to surgery followed by radio(chemo)therapy (radiotherapy plus/minus concurrent chemotherapy). PATIENTS AND METHODS: Data from 148 patients treated with radiochemotherapy alone were matched to 148 patients treated with surgery plus radio(chemo)therapy. Groups were matched 1:1 for nine potential prognostic factors including age, gender, performance status, tumor site, histologic grade, T category, N category, AJCC stage, and hemoglobin level before radiotherapy, and compared for locoregional control, metastases-free survival, and overall survival. RESULTS: Locoregional control rates at 1, 2, and 3 years were 81%, 73%, and 67% after surgery plus radio(chemo)therapy and 81%, 74%, and 65% after radiochemotherapy alone (p = 0.89). Metastases-free survival rates were 86%, 80%, and 75% after surgery plus radio(chemotherapy) versus 87%, 80%, and 72% after radiochemotherapy alone (p = 0.57). Overall survival rates were 80%, 64%, and 63% after surgery plus radio(chemo)therapy versus 83%, 68%, and 60% after radiochemotherapy alone (p = 0.96). On multivariate analyses, T category (p < 0.001), N category (p = 0.004), and hemoglobin level prior to radiotherapy (p < 0.001) were associated with locoregional control. Histologic grade (p = 0.045), T category (p < 0.001), N category (p = 0.003), and hemoglobin level prior to radiotherapy (p < 0.001) were associated with metastases-free survival. Histologic grade (p = 0.030), ECOG performance status (p = 0.033), T category (p = 0.007), N category (p = 0.024) and hemoglobin level before radiotherapy (p < 0.001) were associated with overall survival. CONCLUSION: Outcomes of radiochemotherapy alone appeared similar to those of surgery plus radio(chemo)therapy. Randomized trials comparing both treatments for different tumor sites are warranted.
Authors: Volker Budach; Martin Stuschke; Wilfried Budach; Michael Baumann; Dirk Geismar; Gerhard Grabenbauer; Ingrid Lammert; Klaus Jahnke; Georg Stueben; Thomas Herrmann; Michael Bamberg; Peter Wust; Wolfgang Hinkelbein; Klaus-Dieter Wernecke Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: T G Wendt; G G Grabenbauer; C M Rödel; H J Thiel; H Aydin; R Rohloff; T P Wustrow; H Iro; C Popella; A Schalhorn Journal: J Clin Oncol Date: 1998-04 Impact factor: 44.544
Authors: Hendrik Andreas Wolff; Jan Bosch; Klaus Jung; Tobias Overbeck; Steffen Hennies; Christoph Matthias; Clemens F Hess; Ralph M Roedel; Hans Christiansen Journal: Strahlenther Onkol Date: 2010-04-26 Impact factor: 3.621
Authors: A Becker; P Stadler; R S Lavey; G Hänsgen; T Kuhnt; C Lautenschläger; H J Feldmann; M Molls; J Dunst Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-15 Impact factor: 7.038
Authors: M R Posner; C M Norris; L J Wirth; D M Shin; K J Cullen; E W Winquist; C R Blajman; E A Mickiewicz; G P Frenette; L F Plinar; R B Cohen; L M Steinbrenner; J M Freue; V A Gorbunova; S A Tjulandin; L E Raez; D R Adkins; R B Tishler; M R Roessner; R I Haddad Journal: Ann Oncol Date: 2009-01-29 Impact factor: 32.976
Authors: S A Leibel; C B Scott; M Mohiuddin; V A Marcial; L R Coia; L W Davis; Z Fuks Journal: Int J Radiat Oncol Biol Phys Date: 1991-08 Impact factor: 7.038
Authors: A K Due; I R Vogelius; M C Aznar; S M Bentzen; A K Berthelsen; S S Korreman; C A Kristensen; L Specht Journal: Strahlenther Onkol Date: 2012-05-13 Impact factor: 3.621
Authors: Hendrik Andreas Wolff; Friedrich Ihler; Nina Zeller; Christian Welz; Klaus Jung; Martin Canis; Wolfgang Steiner Journal: Eur Arch Otorhinolaryngol Date: 2015-04-12 Impact factor: 2.503
Authors: M Hata; T Taguchi; I Koike; G Nishimura; M Takahashi; M Komatsu; D Sano; K Odagiri; Y Minagawa; T Inoue Journal: Strahlenther Onkol Date: 2012-11-18 Impact factor: 3.621
Authors: D Dionysopoulos; K Pavlakis; V Kotoula; E Fountzilas; K Markou; I Karasmanis; N Angouridakis; A Nikolaou; K T Kalogeras; G Fountzilas Journal: Strahlenther Onkol Date: 2013-02-13 Impact factor: 3.621
Authors: M Hata; I Koike; J Maegawa; A Kaneko; K Odagiri; T Kasuya; Y Minagawa; H Kaizu; Y Mukai; T Inoue Journal: Strahlenther Onkol Date: 2012-10-28 Impact factor: 3.621
Authors: H A Wolff; C R M Wolff; C F Hess; K Jung; S Sennhenn-Kirchner; M Hinterthaner; A Müller-Dornieden; W Körber; K Marten-Engelke; R Roedel; H Christiansen; C Engelke Journal: Strahlenther Onkol Date: 2013-07-12 Impact factor: 3.621